Search
Search Results
-
HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy
Recent clinical evidence shows that the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) can successfully treat patients with advanced...
-
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
This prospective cohort study reports aneuploidy score by mFast-SeqS as a strong prognostic marker in MBC patients. mFAST-SeqS is an affordable and...
-
The NCI-MATCH trial: lessons for precision oncology
The NCI-MATCH (Molecular Analysis for Therapy Choice) trial ( NCT02465060 ) was launched in 2015 as a genomically driven, signal-seeking precision...
-
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44...
-
Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer
The development of increased knowledge of the interaction between cancer cells, immune cells, and the tumor microenvironment is of special interest...
-
Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives
Advancements in genoty** and sequencing technologies have driven the rapid progress in human genetics research over the last 20 years. Particularly...
-
Clinical trial design in the era of precision medicine
Recent rapid biotechnological breakthroughs have led to the identification of complex and unique molecular features that drive malignancies....
-
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients...
-
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
BackgroundChildren with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This...
-
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
BackgroundPrevious clinical trials have demonstrated the potential efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients...
-
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing panel tests, pediatric patients with extracranial solid...
-
Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)
BackgroundFor patients with liver-confined metastatic colorectal cancer (mCRC), local therapy of isolated metastases has been associated with...
-
Rare subtypes of triple negative breast cancer: Current understanding and future directions
Rare subtypes of triple-negative breast cancers (TNBC) are a heterogenous group of tumors, comprising 5–10% of all TNBCs. Despite accounting for an...
-
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types,...
-
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib...
-
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW (
NCT03037385 ...
-
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
BackgroundAberrant fibroblast growth factor receptor (FGFR) signaling can substantially influence oncogenicity. Despite that FGFR gene abnormality is...
-
Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope
Immune checkpoint inhibitors (ICIs) have revolutionized the approach to cancer management in the recent decade. In the physiological state, the...
-
Application of Monolayer Cell Cultures for Investigating Basic Mechanisms of Photodynamic Therapy
Conventional monolayer cell cultures continue to be an inexpensive and highly accessible model of human disease that can be easily harnessed to study...
-
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer
BackgroundBladder cancer poses a significant public health burden, with high recurrence and progression rates in patients with non-muscle-invasive...
